Ascletis Pharma Inc. (01672) Releases February 2026 Monthly Return on Movements in Securities

Bulletin Express15:22

Ascletis Pharma Inc. (01672) disclosed its Monthly Return on Movements in Securities for the period ended 28 February 2026. The total authorized share capital remained at 7.00 billion ordinary shares, with each share carrying a par value of USD 0.0001, equating to a total authorized share capital of USD 700,000.

At the close of the preceding month, 991.87 million issued shares (excluding 7.08 million treasury shares) were outstanding, bringing total issued shares to 998.96 million. During the month, 69.26 million ordinary shares were issued, resulting in 1.06 billion issued shares (excluding 7.08 million treasury shares) at the end of February 2026, while total issued shares (including treasury shares) reached approximately 1.07 billion.

The company confirmed that it satisfied the applicable public float requirement of 25%. According to disclosures, there were 800,000 shares repurchased in April 2025 and 4.99 million shares repurchased between October and December 2025 that have not yet been cancelled as of 28 February 2026. A placing of 69.26 million new shares at HKD 12.18 took place on 10 February 2026 based on a placing agreement signed on 3 February 2026.

No other warrants, convertible bonds, or additional share arrangements were reported for the month of February 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1120829773?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-03 15:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1120829773","market":"hk","top_or_hot":-1,"title":"Ascletis Pharma Inc. (01672) Releases February 2026 Monthly Return on Movements in Securities","media":"Bulletin Express","content":"<p>Ascletis Pharma Inc. (01672) disclosed its Monthly Return on Movements in Securities for the period ended 28 February 2026. The total authorized share capital remained at 7.00 billion ordinary shares, with each share carrying a par value of USD 0.0001, equating to a total authorized share capital of USD 700,000.</p>\n<p>At the close of the preceding month, 991.87 million issued shares (excluding 7.08 million treasury shares) were outstanding, bringing total issued shares to 998.96 million. During the month, 69.26 million ordinary shares were issued, resulting in 1.06 billion issued shares (excluding 7.08 million treasury shares) at the end of February 2026, while total issued shares (including treasury shares) reached approximately 1.07 billion.</p>\n<p>The company confirmed that it satisfied the applicable public float requirement of 25%. According to disclosures, there were 800,000 shares repurchased in April 2025 and 4.99 million shares repurchased between October and December 2025 that have not yet been cancelled as of 28 February 2026. A placing of 69.26 million new shares at HKD 12.18 took place on 10 February 2026 based on a placing agreement signed on 3 February 2026.</p>\n<p>No other warrants, convertible bonds, or additional share arrangements were reported for the month of February 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ascletis Pharma Inc. (01672) Releases February 2026 Monthly Return on Movements in Securities</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAscletis Pharma Inc. (01672) Releases February 2026 Monthly Return on Movements in Securities\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-03 15:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Ascletis Pharma Inc. (01672) disclosed its Monthly Return on Movements in Securities for the period ended 28 February 2026. The total authorized share capital remained at 7.00 billion ordinary shares, with each share carrying a par value of USD 0.0001, equating to a total authorized share capital of USD 700,000.</p>\n<p>At the close of the preceding month, 991.87 million issued shares (excluding 7.08 million treasury shares) were outstanding, bringing total issued shares to 998.96 million. During the month, 69.26 million ordinary shares were issued, resulting in 1.06 billion issued shares (excluding 7.08 million treasury shares) at the end of February 2026, while total issued shares (including treasury shares) reached approximately 1.07 billion.</p>\n<p>The company confirmed that it satisfied the applicable public float requirement of 25%. According to disclosures, there were 800,000 shares repurchased in April 2025 and 4.99 million shares repurchased between October and December 2025 that have not yet been cancelled as of 28 February 2026. A placing of 69.26 million new shares at HKD 12.18 took place on 10 February 2026 based on a placing agreement signed on 3 February 2026.</p>\n<p>No other warrants, convertible bonds, or additional share arrangements were reported for the month of February 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01672","symbol_name":"歌礼制药-B","start_time":0,"source_url":"","article_id":"1120829773","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1120829773","pubTimestamp":1772522538,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Ascletis Pharma Inc. (01672) disclosed its Monthly Return on Movements in Securities for the period ended 28 February 2026. The total authorized share capital remained at 7.00 billion ordinary...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01672":"歌礼制药-B"},"translate_title":"歌礼制药(01672)发布2026年2月证券变动月报表","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01672":1},"content_text":"Ascletis Pharma Inc. (01672) disclosed its Monthly Return on Movements in Securities for the period ended 28 February 2026. The total authorized share capital remained at 7.00 billion ordinary shares, with each share carrying a par value of USD 0.0001, equating to a total authorized share capital of USD 700,000.\nAt the close of the preceding month, 991.87 million issued shares (excluding 7.08 million treasury shares) were outstanding, bringing total issued shares to 998.96 million. During the month, 69.26 million ordinary shares were issued, resulting in 1.06 billion issued shares (excluding 7.08 million treasury shares) at the end of February 2026, while total issued shares (including treasury shares) reached approximately 1.07 billion.\nThe company confirmed that it satisfied the applicable public float requirement of 25%. According to disclosures, there were 800,000 shares repurchased in April 2025 and 4.99 million shares repurchased between October and December 2025 that have not yet been cancelled as of 28 February 2026. A placing of 69.26 million new shares at HKD 12.18 took place on 10 February 2026 based on a placing agreement signed on 3 February 2026.\nNo other warrants, convertible bonds, or additional share arrangements were reported for the month of February 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1120829773","isCrawlerRequest":true}